Active and passive immunization for cancer
Author:
Open Access
- 7 July 2014
- journal article
- review article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (7) , 2123-2129
Abstract
Vaccination started around the 10th century AD as a means of preventing smallpox. By the end of the 19th century such therapeutic vaccines were well established with both active and passive preparations being used in clinical practice. Active immunization involved administering an immunogen that might be live/ attenuated, killed/ inactivated, toxoid or subunit in origin. Passive immunization involved giving pre-formed antibodies, usually to very recently exposed individuals. At about the same time such approaches were also tried to treat a variety of cancers – proof of principle for the protective role of the immune response against malignancy was established by the observation that tumors transplanted into syngeneic hosts were rejected by the host innate and adaptive responses. The impact of these therapeutic vaccination has taken a considerable time to become established - in part because target antigens against which an adaptive response can be directed do not appear to be uniquely expressed on maligna...Keywords
This publication has 22 references indexed in Scilit:
- Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancerBritish Journal of Cancer, 2013
- Targeted drug delivery for cancer therapy: the other side of antibodiesJournal of Hematology & Oncology, 2012
- Antibody therapy of cancerNature Reviews Cancer, 2012
- Translating Tumor Antigens into Cancer VaccinesClinical and Vaccine Immunology, 2011
- Adoptive T cell therapy for cancer in the clinicJournal of Clinical Investigation, 2007
- A brief history of the prevention of infectious diseases by immunisationsComparative Immunology, Microbiology and Infectious Diseases, 2003
- Immune Mechanisms in Bacillus Calmette-Guerin Immunotherapy for Superficial Bladder CancerJournal of Urology, 2003
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Immunogenetics of Human Cell Surface DifferentiationAnnual Review of Immunology, 1989
- CONTRIBUTION TO THE KNOWLEDGE OF SARCOMAAnnals of Surgery, 1891